PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1518502
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1518502
In-situ Hybridization Market Size - By Product (Consumables, Instruments, Services), Technology (Fluorescent In-Situ Hybridization, Chromogenic In-Situ Hybridization), Application (Cancer, Cytogenetics, Immunology), End-use & Forecast 2024 - 2032
Global In-situ Hybridization Market size will expand at an 8.6% CAGR from 2024 to 2032, attributed to advancements in molecular biology coupled with increasing demand for personalized medicine. These innovations enable precise genetic and molecular profiling, which is crucial for personalized treatment strategies. As healthcare shifts towards tailored therapies based on individual genetic profiles, there is a growing need for accurate diagnostic tools like in-situ hybridization. This trend drives ongoing research and development, enhancing the sensitivity and specificity of in-situ hybridization assays and thus expanding their applications across oncology, infectious diseases, and genetic disorders.
For instance, in December 2023, Cytelabs introduced DISH testing for breast cancer, a specialized oncopathology diagnostic service launched in collaboration with Cytecare Cancer Hospital. It is increasingly used to determine HER2 status in breast cancer patients, marking a substantial advancement in cancer diagnostics. It highlights a trend towards personalized medicine and precision oncology, influencing market dynamics by enhancing diagnostic accuracy and treatment efficacy for breast cancer and possibly other oncological conditions.
The in-situ hybridization industry is divided based on product, technology, application, end-use, and region.
The chromogenic in-situ hybridization segment will establish a noteworthy foothold through 2032, owing to its simplicity, cost-effectiveness, and wide applicability in cancer diagnostics and molecular pathology. This method's ability to visualize gene expression patterns with high sensitivity and specificity makes it essential in clinical and research settings. As demand grows for precise disease diagnosis and personalized medicine, the chromogenic in-situ hybridization technique will maintain its dominance, catering to increasing healthcare needs globally.
The developmental biology segment will experience a considerable upturn by 2032, propelled by its critical role in studying gene expression patterns during embryonic development and tissue differentiation. This technique enables precise localization of mRNA and DNA sequences within cells and tissues, supporting research in developmental processes and organogenesis. As scientific advancements in developmental biology accelerate, the demand for in-situ hybridization techniques to elucidate complex biological mechanisms will grow, solidifying the segment's significant position in molecular biology research.
Asia Pacific in-situ hybridization market share will record a remarkable CAGR between 2024 and 2032, fueled by increasing healthcare expenditure, rising incidence of chronic diseases, and expanding biotechnology research. Countries like China, India, and Japan are pivotal, driving demand for advanced diagnostic techniques. Factors such as government initiatives and investments in healthcare infrastructure further bolster market growth in the region. These dynamics position Asia Pacific as a primary contributor to the in-situ hybridization industry, fostering innovation and technological advancements in molecular diagnostics.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of target disorders
- 3.2.1.2 Technological advancement in the field of in-vitro diagnostics
- 3.2.1.3 Rising R&D investments in in-vitro diagnostics
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of in-situ hybridization
- 3.2.2.2 Presence of an ambiguous regulatory framework
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Consumables
- 5.2.1 Probes
- 5.2.2 Kits and reagents
- 5.2.3 Accessories
- 5.3 Instruments
- 5.4 Services
Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Fluorescent in-situ hybridization
- 6.2.1 DNA fluorescent in-situ hybridization
- 6.2.2 RNA fluorescent in-situ hybridization
- 6.2.3 PNA fluorescent in-situ hybridization
- 6.3 Chromogenic in-situ hybridization
Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Cancer
- 7.3 Cytogenetics
- 7.4 Developmental biology
- 7.5 Infectious diseases
- 7.6 Neuro science
- 7.7 Immunology
- 7.8 Other applications
Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals and diagnostic laboratories
- 8.3 Academic and research institutes
- 8.4 Contract research organizations
- 8.5 Pharmaceuticals and biotechnology companies
- 8.6 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Agilent Technologies, Inc.
- 10.2 Bio-Techne Corporation
- 10.3 Bio-Rad Laboratories, Inc.
- 10.4 Bio View Ltd.
- 10.5 Danaher Corporation
- 10.6 Merck KGaA
- 10.7 Neogenomics, inc.
- 10.8 PerkinElmer, Inc.
- 10.9 Sysmex Corporation
- 10.10 Thermo Fisher Scientific Inc.
